ArticleJournal of psychopharmacology (Oxford, England)2026
α
Article in Journal of psychopharmacology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNegative allosteric modulators (NAMs) of gamma-aminobutyric acid (GABA
aimThis study aimed to investigate the effects of L-655,708 on the monoamine and glutamate systems in rats in relation to the antidepressant-like response.
methodsMale Sprague-Dawley rats received a single dose of L-655,708 (3 mg/kg, i.p.) or vehicle. In vivo extracellular recordings were conducted in the dorsal raphe nucleus (DRN), locus coeruleus (LC), ventral tegmental area (VTA), and medial prefrontal cortex (mPFC) acutely, 1 day, 1 week, and 2 weeks post-injection. AMPA and N-methyl-D-aspartate (NMDA) responsiveness in the hippocampal CA1 region was assessed using microiontophoresis.
resultsThe NMDA-induced response in the CA1 hippocampus was significantly reduced 1 day post-injection of L655,708, while the AMPA response remained unchanged. Although mPFC pyramidal neurons' firing was not changed, there was a two-fold increase in population activity of VTA dopamine (DA) neurons 1 day post-injection, lasting up to 1 week. Flumazenil, the benzodiazepine site antagonist, and 2,3-dioxo-6-nitro-7-sulfamoyl-benzo[f]quinoxaline (NBQX), an AMPA receptor antagonist, blocked this effect. L-655,708 had no acute effect on firing activity of serotonin or norepinephrine neurons.
conclusionL-655,708 enhanced VTA DA neuron population activity for up to 1 week after a single injection. This effect was dependent on AMPA and took place through action on the benzodiazepine site.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.